Ocrelizumab

Product Name: Ocrelizumab
CAS No.: 637334-45-3
Chemical Name: Ocrelizumab
Synonyms: Ocrelizumab;Ocrelizumab (anti-CD20);Research Grade Ocrelizumab;Research Grade Ocrelizumab(DHC90702)
CBNumber: CB23039319
Molecular Formula: C19H16N2O5
Formula Weight: 0
MOL File: Mol file

More

Less

Ocrelizumab Property

form: Liquid
color: Colorless to light yellow

More

Less

Safety

Hazardous Substances Data: 637334-45-3(Hazardous Substances Data)

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

Ocrelizumab Chemical Properties,Usage,Production

History

The development of Ocrelizumab, sold under the brand name Ocrevus, starts with rituximab, another monoclonal antibody (MAb) that was developed for the treatment of autoimmune disorders and was approved for the treatment of CD20-positive follicular non-Hodgkin lymphoma in 1994. However, rituximab is a chimeric MAb and is immunogenic in humans, and the manufacturer decided to focus on the similar but fully humanized MAb, ocrelizumab, for multiple sclerosis instead. It was granted approval by the U.S. Food and Drug Administration (FDA) in 2017 as the first treatment indicated for both relapsing and primary progressive forms of multiple sclerosis.Ocrelizumab has also been approved by the European Medicines Agency.

Uses

Treatment of rheumatoid arthritis.

in vivo

Ocrelizumab (7.5 mg/kg; once daily; 18 days; s.c. or i.v.) inhibits lesions in multiple sclerosis mice by inducing B cell exhaustion through antibody dependent cytotoxicity (ADCC)^[1]. Ocrelizumab (50 μg; repeat administration on days 7, 14, and 21; i.v.) can reduce B and T cells in the blood, lymph nodes, and spleen of C57BL/6 mice^[2].

Animal Model:	HuCD20 mice with chronic DTH-TLS lesions^[1].
Dosage:	7.5 mg/kg
Administration:	Subcutaneous injection (s.c.) or intravenous injection (i.v.); once daily; 18 days; initiated on Days 63, 70 and 75 post lesion induction
Result:	Reduced the number of CD19+ cells and MS like lesions in the spleen and lymph nodes of mice.

Animal Model:	C57BL/6 mice ^[2].
Dosage:	50 μg
Administration:	Intravenous injection (i.v.); repeat administration on days 7, 14, and 21
Result:	Reduced the total CD19+ B cells and CD4, CD8 T cells in the blood, spleen, and LN.

Ocrelizumab Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

Ocrelizumab Suppliers

China 34 United States 1 USA 1 Global 36

Wuhan Sunrise Technology Development Co., Ltd.

Tel: 27-027-83314682 13554138826
Fax: +86 (27) 8331-4682
Email: whsrtech@vip.163.com
Country: China
ProdList: 246
Advantage: 62

Nanjing Sunlida Biological Technology Co., Ltd.

Tel: 025-57798810
Fax: 025-57019371
Email: sales@sunlidabio.com
Country: China
ProdList: 3239
Advantage: 55

Shanghai EFE Biological Technology Co., Ltd.

Tel: 021-65675885 18964387627
Fax: 021-65675885
Email: info@efebio.com
Country: China
ProdList: 9803
Advantage: 58

Shanghai YuanYe Biotechnology Co., Ltd.

Tel: 021-61312847; 18021002903
Fax: QQ:3008007432
Email: 3008007409@qq.com
Country: China
ProdList: 71826
Advantage: 60

ShangHai Biochempartner Co.,Ltd

Tel: 177-54423994 17754423994
Fax: QQ:2853530913
Email: 2853530910@QQ.com
Country: China
ProdList: 8000
Advantage: 62

Hefei Hirisun Pharmatech Co., Ltd.

Tel: +86-0551-62678551 +86-15056975894
Fax: 05512678551
Email: sales@hirisunpharm.com
Country: China
ProdList: 176
Advantage: 55

Shanghai Biopharmaleader Co., Ltd.

Tel: +86 18721201413
Fax: +86 (21) 5775-8967
Email: sales@biopharmaleader.com
Country: China
ProdList: 1720
Advantage: 58

AFINE CHEMICALS LIMITED

Tel: +86-0571-85134551
Fax: 008657185134895
Email: sales@afinechem.com
Country: China
ProdList: 15107
Advantage: 58

Guangzhou Hongyuan Chemical Co.,Ltd

Tel: 15817493340
Email: 981810490@qq.com
Country: China
ProdList: 1566
Advantage: 58

Jiangsu Greature Bio-Medicine Co., Ltd.

Tel: 0512-85557988 18662338937
Fax: 0512-85557182
Email: frank.wang@greature.com.cn
Country: China
ProdList: 147
Advantage: 58

Wuhan Chemstan Biotechnology Co., Ltd.

Tel: 027-65317797 15926423062
Fax: QQ：422450190
Email: 422450190@qq.com
Country: China
ProdList: 10308
Advantage: 58

Shanghai Minkai Biological Technology Co., Ltd

Tel: 021-021-52919136 17315815539
Email: 2804155403@qq.com
Country: China
ProdList: 180
Advantage: 58

Jiangxi ravel Biotechnology Co.,Ltd

Tel: 400-880-2824 18107960669
Fax: 18140514863
Email: 79046690@qq.com
Country: China
ProdList: 1242
Advantage: 58

Bide Pharmatech Ltd.

Tel: 400-1647117 13681763483
Email: product02@bidepharm.com
Country: China
ProdList: 59936
Advantage: 58

Jiangxi ravel Biotechnology Co.,Ltd

Tel: 185-0276-2003 18502762003;
Email: 435918333@qq.com
Country: China
ProdList: 2213
Advantage: 58

Biolab Reagents

Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Country: China
ProdList: 9868
Advantage: 58

Wuhan Jingkangen Biomedical Technology Co., Ltd

Tel: 13720134139 086-15871494362 13720134139
Email: orders@jknbiochem.com
Country: China
ProdList: 6762
Advantage: 58

Nantong QuanYi Biotechnology Co., Ltd

Tel: 0513-66337626 18051384581
Email: sales@chemhifuture.com
Country: China
ProdList: 5929
Advantage: 58

Wuhan Acumen Bio-Technology Co.,ltd

Tel: 027-027-16602739303 16602739303
Email: 673003916@qq.com
Country: China
ProdList: 2935
Advantage: 58

Shanghai Aladdin Biochemical Technology Co.,Ltd.

Tel: 400-6206333 13167063860
Email: anhua.mao@aladdin-e.com
Country: China
ProdList: 48457
Advantage: 58

Changsha Fuzhen Biotechnology Co.，LTD

Tel: 0731-13823398 15111215862
Email: 313359644@qq.com
Country: China
ProdList: 4161
Advantage: 58

Hubei wei shi reagent group ltd., company

Tel: 027-59102966 18717199209
Email: 2853877583@QQ.com
Country: China
ProdList: 7500
Advantage: 58

Hubei wei shi reagent group ltd., company

Tel: 027-59101766 13125137661
Email: 2853877621@qq.com
Country: China
ProdList: 7979
Advantage: 58

Olix (Shanghai) Pharmaceutical Technology Co., Ltd

Tel: 17316404525 17316404525
Email: 209533805@qq.com
Country: China
ProdList: 9763
Advantage: 58

Wanxin Biotechnology (Jiaxing) Co., LTD

Tel: 0573-83568680 18057391398
Email: 3956524501@qq.com
Country: China
ProdList: 1442
Advantage: 58

Atagenix Laboratories

Tel: 027-87008169 17762441161
Email: info@atagenix.com
Country: China
ProdList: 10001
Advantage: 58

AntibodySystem Laboratories SAS

Tel: 33175446423
Email: support@antibodysystem.com
Country: China
ProdList: 6739
Advantage: 58

Biosynth Biological Technology (Suzhou) Co Ltd

Tel: 51288865780
Email: sales@biosynth.com
Country: China
ProdList: 6051
Advantage: 58

Selleck Chemicals

Tel: 400-668-6834
Email: info@selleck.cn
Country: China
ProdList: 6071
Advantage: 58

Cell Sciences

Tel: 9785721070
Email: info@cellsciences.com
Country: China
ProdList: 6308
Advantage: 58

Suzhou Genelee Bio-Technology Co., Ltd

Tel: 86-17715515539 17715515539
Email: James@geneleebio.com
Country: China
ProdList: 41
Advantage: 58

Zibo Hangyu Biotechnology Development Co., Ltd

Tel: +86-0533-2185556 +8615965530500
Email: nickzhang@hangyubiotech.com
Country: China
ProdList: 8510
Advantage: 58

Guangzhou Suyan Biotechnology Co., Ltd

Tel: 18818417021
Country: CHINA
ProdList: 127
Advantage: 58

Guangzhou Chuangze Biotechnology Co., Ltd.

Tel: 18312220236
Country: CHINA
ProdList: 178
Advantage: 58

637334-45-3, OcrelizumabRelated Search:

Stamulumab Leronlimab Gemtuzumab palivizumab Tefibazumab Ganitumab Telisotuzumab Lebrikizumab Tusamitamab EFALIZUMABUM

Ocrelizumab

Research Grade Ocrelizumab(DHC90702)

Ocrelizumab (anti-CD20)

Research Grade Ocrelizumab

637334-45-3